Monoclonal Gammopathy of Undetermined Significance

Kyle, Robert A.; Rajkumar, S. Vincent

doi:10.1007/978-1-4614-3764-2_38

Cited by 11 publications

(14 citation statements)

References 344 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MBL is a monoclonal gammopathy with no evidence of lymphoproliferative disease, but the cells have a chronic lymphocytic leukaemia (CLL) immunophenotype with rare progression to CLL (1%‐2% per year) . Genetic risk factors have been identified in both of these disorders and they are thought to represent a pre‐neoplastic state . TCUS may represent a similar process for T cells, but it is difficult to equate the process in people with what we have described here in dogs, because T cell clonality in people is not defined by DNA‐based clonality assessment but by expansion of a family of T cells that use the same Vb gene, but that do not have identical TCRs …”

Section: Discussionmentioning

confidence: 88%

“…MGUS is an asymptomatic plasma cell dyscrasia with low but measurable risk of progressing to multiple myeloma (MM) . MBL is a monoclonal gammopathy with no evidence of lymphoproliferative disease, but the cells have a chronic lymphocytic leukaemia (CLL) immunophenotype with rare progression to CLL (1%‐2% per year) .…”

Section: Discussionmentioning

confidence: 99%

“…In MGUS, patients are monitored throughout their life as the risk of transformation is considered to be life‐long. The risk for development of MM in MGUS is only 1% per year . MBL with a low count (<500 clonal B cells/μL) can be identified in about 5% of adults over 40 years with rare progression to CLL, and in one study, no individuals with a low‐count MBL showed progression to lymphoid neoplasia with a median follow‐up of 34 months .…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Increased frequency of CD45 negative T cells (T zone cells) in older Golden retriever dogs

Hughes

Labadie

Yoshimoto

et al. 2017

Vet Comparative Oncology

View full text Add to dashboard Cite

T zone lymphoma (TZL) is characterized by the clonal expansion of T cells lacking expression of the pan-leukocyte antigen CD45 (TZ cells). A strong breed predisposition is observed in Golden retrievers. This study aimed to confirm aberrant CD45 mRNA expression and determine if Golden retrievers without clinical lymphoma have an increased frequency of circulating TZ cells. Gene expression analysis on confirmed TZL cases showed a significant decrease in CD45 expression compared to normal dogs. Peripheral blood samples from senior dogs, 242 Golden retrievers and 42 non-Golden retrievers, without evidence of lymphoproliferative disease were assessed for the presence of TZ cells by flow cytometry. Thirty-one percent of Golden retrievers had TZ cells compared to 14% of non-Golden retrievers. Thirty-four percent of Golden retrievers with TZ cells had a clonal T cell receptor gamma (TRG) gene rearrangement. Interestingly, 20% of Golden retrievers without TZ cells also had a clonal TRG rearrangement. Golden retrievers may have an increased risk of TZL due to an increased frequency of TZ cells.

show abstract

Section: Discussionmentioning

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Increased frequency of CD45 negative T cells (T zone cells) in older Golden retriever dogs

Hughes

Labadie

Yoshimoto

et al. 2017

Vet Comparative Oncology

View full text Add to dashboard Cite

show abstract

“…Monoclonal gammopathy of undetermined significance (MGUS) is a common condition that is defined by a serum monoclonal (M) protein of κ or λ type, but it does not fulfill other criteria for malignant disease . The prevalence in the general population increases with age and is 4% in whites older than age 50 .…”

Section: Introductionmentioning

confidence: 99%

Donor Monoclonal Gammopathy May Cause Lymphoproliferative Disorders in Solid Organ Transplant Recipients

Felldin

Ekberg

Polanska-Tamborek

et al. 2016

American Journal of Transplantation

View full text Add to dashboard Cite

Prior research on donor monoclonal gammopathy of undetermined significance (MGUS) has been inadequate regarding the risk for lymphoproliferative disease in solid organ transplantation recipients. Seven organ recipients from two different donors developed lymphoproliferative disease. The origin of the malignancy was determined by use of microsatellite analysis, and the plasma of the two donors was analyzed with the use of electrophoresis. The clinical courses of the seven recipients were followed for 36–60 months. One donor transmitted lymphoplasmacytic lymphoma to two kidney recipients and MGUS to a liver recipient, all IgMκ. A second donor caused IgGλ myeloma in two kidney and one liver recipient, and IgGλ gammopathy in a heart recipient. Transplant nephrectomy was performed in three kidney recipients and remission was achieved. The fourth kidney recipient has kept the graft and the disease has progressed. The liver recipient died from myeloma. There were no clinical signs of lymphoproliferative disease in the donors, but retrospective serum analyses showed M‐components, IgMκ (37 g/L) and IgGλ (8 g/L). Donors with MGUS may cause donor‐transmitted malignancies via passenger lymphocytes/plasma cells in solid organ recipients. The results call for a large register study of the incidence of donor MGUS and lymphoproliferative disease in their recipients.

show abstract

“…Standard diagnostic criteria for MGUS require a serum M protein <3.0 g/dL, clonal bone marrow plasma cells <10%, and absence of end‐organ damage such as osteolytic bone lesions, anemia, renal failure, or hypercalcemia that can be attributed to the underlying monoclonal gammopathy . Although these criteria are explicit that a bone marrow evaluation to determine extent of plasmacytosis is required to make a diagnosis of MGUS, universal application of this test to clinical practice is sometimes difficult to justify because the procedure is cumbersome and expensive . Therefore, elderly patients with small M proteins and no evidence of end‐organ damage are often diagnosed as MGUS based on other clinical and laboratory parameters without a bone marrow biopsy being performed.…”

mentioning

confidence: 99%